EDITORIAL

323 Black Diabetic Lives Matter
Stephen A. Brunton

CLINICAL DIABETES DIGITAL PUBLICATION

324 Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk: Executive Summary
John Anderson, Scott Urquhart, Geralyn Spollett, and Paresh Dandona

FEATURE ARTICLES

328 Prediabetes Deserves More Attention: A Review
Yakubu Lawal, Fatima Bello, and Yazid Suleiman Kaoje

339 How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?
Joseph Tibaldi, Max E.Mercado, and Jodi Strong

348 The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring
Pamela R. Kushner and Davida F. Kruger

357 Impact of Participation in a Virtual Diabetes Clinic on Diabetes-Related Distress in Individuals With Type 2 Diabetes, William H. Polonsky, Jennifer E. Layne, Christopher G. Parkin, Coco M. Kusiak, Nathan A. Barleen, David P. Miller, Howard Zisser, and Ronald F. Dixon

363 Race Disparities in the Use of Prevention, Screening, and Monitoring Services in Michigan Medicare Beneficiaries With Type 2 Diabetes and Combinations of Multiple Chronic Conditions
John Michael Clemens, Brady Thomas West, Batoul Harissa, Nolan Hayden, Mishaal Mustafa Khan, and Raghuram Palepu

PERSPECTIVES IN CLINICAL DIABETES

371 Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association
Robert A. Gabbay, Debbie Kendall, Christine Beebe, John Cuddeback, Todd Hobbs, Naeem D. Khan, Sandra Leal, Eden Miller, Lucia M. Novak, Swapnil N. Rajpathak, Paul Scribner, Luigi Meneghini, and Kamlesh Khunti

QUALITY IMPROVEMENT SUCCESS STORIES

382 Design and Implementation of an Electronic Tool to Measure Medication Adherence at the Point of Care

386 Strategies to Improve Annual Diabetic Foot Screening Compliance at a Family Clinic
Carlie Cooksey

PRACTICAL POINTERS

390 Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Jaime P. Almandoz, Ildiko Lingvay, Javier Morales, and Carlos Campos

PATIENT INFORMATION

403 Race and Type 2 Diabetes

CLINICAL PHARMACOLOGY UPDATE

405 Bempedoic Acid: A Novel LDL Cholesterol-Lowering Agent, Kylee Shriver

CASE STUDIES

408 Diabetic Ketoacidosis in a Type 2 Diabetes Patient After Initiation of Over-the-Counter Weight Loss Medications: A Cautionary Tale
Kamilya A. Gosmanova and Aidar R. Gosmanov

412 Incorporation of the Ketogenic Diet in a Youth With Type 1 Diabetes
Fran R. Cogen